Clinical Trials · NCT07229157
Effect of Maridebart Cafraglutide on the Heart's Electrical Activity
- Phase
- Phase 1
- Recruitment status
- Active Not Recruiting
- Sponsor
- Amgen
- Enrollment
- 81
- Start date
- Oct 2025
- Locations
- 2 sites, United States
- Primary endpoint
- Change from Baseline in QTcF for Maridebart Cafraglutide